PA32540

POZEN's NDA for PA32540/PA8140 tablets accepted by FDA for review

POZEN's NDA for PA32540/PA8140 tablets accepted by FDA for review

Yahoo/Fly on the Wall

POZEN Submits New Drug Application for PA32540/PA8140

POZEN Submits New Drug Application for PA32540/PA8140

Yahoo

POZEN's PA32540 shows posiive results in a Phase 1 study

POZEN's PA32540 shows posiive results in a Phase 1 study

Yahoo/Fly on the Wall

Pozen rises on continued FDA drug discussions

Pozen rises on continued FDA drug discussions

Yahoo/AP

FDA says Pozen ulcer drug may need more data, shares plunge

FDA says Pozen ulcer drug may need more data, shares plunge

Reuters

PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole (40 Mg)

PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole (40 Mg)

The Street

Pozen rises as ulcer drug meets goals in studies

Pozen rises as ulcer drug meets goals in studies

Yahoo/AP

Pozen's Final Results On Ulcer Safe Aspirin Can Send Shares Soaring

Pozen's Final Results On Ulcer Safe Aspirin Can Send Shares Soaring

Seeking Alpha

Change of heart: Why Pozen now wants to partner its cardiovascular drug

Change of heart: Why Pozen now wants to partner its cardiovascular drug

Med City